Effect of Platelet Inhibition According to Clopidogrel Dose in Patients With Chronic Kidney Disease
CompletedPhase 4NCT01328470
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Impaired renal function is associated with reduced responsiveness to clopidogrel. There are no studies which have shown a means by which to overcome platelet hyporesponsiveness in patients with chronic kidney disease (CKD). The purpose of this study was to determine the functional impact of cilostazol in patients with CKD undergoing hemodialysis.
Study details
- Official title
- Platelet Reactivity in Patients With Chronic Kidney Disease Receiving Adjunctive Cilostazol Compared to a High-maintenance Dose of Clopidogrel
- Conditions
- Chronic Kidney Disease
- Stable Angina
- Interventions
- Drug: Clopidogrel, cilostazol
- Sponsor
- Kyunghee University Medical Center
- Start date
- 2009-09
- Primary completion
- 2010-08
- Sex
- All
- Age range
- from 20 Years to 80 Years
- Results posted
- No results posted in this snapshot
- Countries
- South Korea
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * CKD patients undergoing chronic hemodialysis and PCI for stable coronary artery disease Exclusion Criteria: * known allergies to aspirin, clopidogrel, or cilostazol thienopyridine use before enrollment * concomitant use of other anti-thrombotic drugs (oral anticoagulants and dipyridamole) * platelet count \<100 x 106/μL * hematocrit \< 25% * liver disease (bilirubin \> 2 mg/dl) * active bleeding or bleeding diathesis * gastrointestinal bleeding within the last 6 months * hemodynamic instability * acute coronary or cerebrovascular event within 3 months * malignancy * concomitant use of a cytochrome P450 inhibitor or a non-steroidal anti-inflammatory drug * recent treatment (\<30 days) with a glycoprotein IIb/IIIa antagonist.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT01328470